


PHARMACEUTICAL 2022

Revance Therapeutics Inc. Rank 316 of 475





REVANCE



PHARMACEUTICAL 2022

Revance Therapeutics Inc. Rank 316 of 475

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Revance Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 110% points.

The company's Economic Capital Ratio, given in the ranking table, is -215%, being 62% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	246,117
Cost of Goods Sold	0
Intangible Assets	202,298
Liabilities, Current	67,289
Liabilities, Non-Current	114,768
Other Assets	58,087
Other Compr. Net Income	-18
Other Expenses	43,671
Other Liabilities	280,635
Other Net Income	-361
Property and Equipment	24,661
Research and Development	116,255
Revenues	77,798
Selling, General and Administrative Expense	198,821

Output Variable	Value in 1000 USD
Assets	531,163
Liabilities	462,692
Expenses	358,747
Stockholders Equity	68,471
Net Income	-281,310
Comprehensive Net Income	-281,319
Economic Capital Ratio	-215%

